Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983468 | 0.89 | CNR1 (0.40) | HTR6CNR1CNR2PIK3CD | |
| SCHEMBL30983559 | 0.89 | PIK3CD (0.40) | CNR1CNR2PIK3CDMAPT | |
| SCHEMBL30983587 | 0.89 | HTR6 (0.36) | HTR6CNR1CNR2PIK3CDMAPT | |
| SCHEMBL31269090 | 0.88 | HTR6 (0.35) | HTR6CNR1PIK3CDHTR1ADRD2 | |
| SCHEMBL30983462 | 0.88 | PIK3CD (0.41) | CNR1CNR2PIK3CDMAPT | |
| SCHEMBL30983425 | 0.86 | PIK3CD (0.38) | HTR6PIK3CD | |
| SCHEMBL31269320 | 0.86 | HTR6 (0.34) | HTR6CNR1PIK3CD | |
| SCHEMBL30983795 | 0.86 | PDE2A (0.42) | HTR6PIK3CDDRD2 | |
| SCHEMBL30983776 | 0.85 | PIK3CD (0.40) | CNR1CNR2PIK3CD | |
| SCHEMBL30983784 | 0.85 | PIK3CD (0.40) | CNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTR6 4806/4885CNR1 4278/4885CNR2 4639/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | HTR6 4806/4885CNR1 4278/4885CNR2 4639/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTR6 4806/4885CNR1 4278/4885CNR2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.